What changed in this filing

/stocks — the workspaceLOADING

Item 2. Properties

2026-03-12 compared with 2025-03-18 · 15 added, 18 removed, 5 unchanged (87% of the section changed)

2 – PROPERTIES

maintain our principal office at 26 Main Street, Suite 101, Chatham, New Jersey 07928.

Our telephone number at that office is

(862) 799-8599 and our fax number is (212) 923-5700.

On August 28, 2020, we entered into a lease, whereby we agreed to lease new

office space, commencing September 2020 and expiring December 2025.

In connection therewith, we maintain a letter of credit, which

has a remaining balance of $144,745 as of December 31, 2024, and such amount is deposited into the restricted cash account maintained

at the bank that issued the letter of credit.

maintain our principal office at 200 Connell Drive, Suite 3, Berkeley Heights, New Jersey 07922.

Our telephone number at that office

is (862) 799-8599 and our fax number is (212) 923-5700.

On July 24, 2025, we entered into a lease, whereby we agreed to lease

new office space, commencing November 2025 and expiring January 2030.

In connection therewith, we maintain a letter of credit,

which has a remaining balance of $386,000 as of December 31, 2025, and such amount is deposited into the restricted cash account

maintained at the bank that issued the letter of credit.

own and operate a research and development facility in Frederick, Maryland used for process development activities.

We own an approximately 44-acre site in Hamilton, Montana, for the construction

of a vaccine development and commercial scale manufacturing facility.

As of December 31, 2024, the facility was not ready for its intended

own a 45,000 square foot facility in North Dartmouth, Massachusetts that houses our Advanced Development (“ADC”), for accelerated development and manufacturing of vaccines.

During the fourth quarter of 2023, the

Company engaged CBRE, an international real estate brokerage firm, to potentially find a strategic partner for, or buyer of, its

During the second quarter of 2024, the Company decommissioned its ADC facility.

As of December 31, 2024, the Company does

not have a commitment in place to sell the ADC.

own an approximately 44-acre site in Hamilton, Montana, for the construction of a vaccine development and commercial scale manufacturing

As of December 31, 2025, the facility was not ready for its intended use.

We own a 45,000 square foot facility in North Dartmouth, Massachusetts

that houses our Advanced Development (“ADC”), for accelerated development and manufacturing of vaccines.

The facility was

decommissioned in 2024 decommissioned and may be reactivated on the earlier of 2027 or in the case of a national or international emergency.

minimum lease payments are as follows (in thousands):

Year Ending December 31,

Included interest

and thereafter

believe that our existing facilities are suitable and adequate to meet our current business requirements.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 2. Properties